TriangleNCT01592383 · OUTCOME
Toxicity
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- Not reported
- Unit
- Not reported
- Interval / dispersion
- Not reported
- Time frame
- 30 days from the last dose of study drug
What was measured
Toxicity is calculated in terms of adverse events per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) criteria version 4.0
Analysis population: The study was terminated early after the enrollment of two participants and the data were not collected.
Groups in this outcome
Treatment (Enzyme Inhibitor Therapy)
Patients receive erlotinib hydrochloride PO QD. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
| Group | Source count |
|---|---|
| Treatment (Enzyme Inhibitor Therapy) | 0 |
Reported measurements
No numerical measurement classes were posted for this outcome. Missing is not zero.
Complete source fields
- denoms
- counts
- group Id
- OG000
- value
- 0
- units
- Participants
- description
- Toxicity is calculated in terms of adverse events per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) criteria version 4.0
- groups
- description
- Patients receive erlotinib hydrochloride PO QD. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
- id
- OG000
- title
- Treatment (Enzyme Inhibitor Therapy)
- population Description
- The study was terminated early after the enrollment of two participants and the data were not collected.
- reporting Status
- POSTED
- time Frame
- 30 days from the last dose of study drug
- title
- Toxicity
- type
- SECONDARY
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice